drugset / Trial / NCT06520345
The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the efficacy and safety of 177Lu-TLX591 in patients with metastatic castration-resistant prostate cancer who have progressed following treatment with Androgen Receptor Pathway Inhibitor Treatment
Timeline
- Start
- 2024-07-26
- Primary completion
- 2027-12
- Completion
- 2030-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 177Lu-TLX591 | Unknown | 2812 mbq | — |
| Background | Abiraterone acetate | Small molecule | 1000 mg | — |
| Background | Docetaxel | Small molecule | 75 mg/m2 | Intravenous |
| Background | Enzalutamide | Other / unclassified | 160 mg | — |